GGrantIndex
← Leaderboards

Janice M. Mehnert

New York University School Of Medicine

$4,684,455
Attributed
$6,547,798
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,547,798 · 8

By mechanism

R01$2,821,504 · 2
UM1$1,468,904 · 1
P30$819,648 · 2
K12$785,410 · 1
R50$332,118 · 1
R21$320,214 · 1

Top collaborators

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsProtocols DocumentationClinical ResearchResponseTumorCancer CenterResearch PersonnelMalignant NeoplasmsFundingGrantInstitutionCellsBiological MarkersMelanomaCollaborationsToxic EffectResearch InfrastructurePathway InteractionsPharmacodynamicsFutureProgramsInnovationLeadCancer Therapy Evaluation Program

Grant awards (19)

K12 Training for Clinical and Translational Oncology Researchers$785,410
K12 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$391,427
P30 · FY2025 · CA · contact PI
“Promoting a Culture Of Innovation, Mentorship, and Clinical Investigation in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D$110,706
R50 · FY2025 · CA · contact PI
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition$563,722
R01 · FY2024 · CA · contact PI
Clinical Protocol and Data Management$391,425
P30 · FY2024 · CA · contact PI
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.$110,706
R50 · FY2024 · CA · contact PI
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.$110,706
R50 · FY2023 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$459,563
R01 · FY2020 · CA
Clinical Investigations and Precision Therapeutics$29,643
P30 · FY2020 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$441,168
R01 · FY2019 · CA
Clinical Investigations and Precision Therapeutics$7,153
P30 · FY2019 · CA · contact PI
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$500,917
UM1 · FY2018 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$448,463
R01 · FY2018 · CA
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$495,652
R01 · FY2017 · CA
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$300,000
UM1 · FY2017 · CA · contact PI
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$100,000
UM1 · FY2017 · CA · contact PI
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics$567,987
UM1 · FY2016 · CA · contact PI
Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanoma$412,936
R01 · FY2016 · CA
A Phase 0 Trial of Hydroxychloroquine in Patients with Stage III and IV Resectabl$320,214
R21 · FY2010 · CA · contact PI